Abiopharma

🔍 Boyle Dana (Executive)

Company: Liquidia Corp (LQDA)

Report Date: 2026-07-27

Detailed Transactions and Holdings:

• Sold 1,600 shares of Common Stock at $87.53 per share (Direct)
  Date: 2026-07-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 167,919.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3

Footnotes:

• F1: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.
• F2: These shares of common stock were sold to cover taxes associated with the settlement of restricted stock units ("RSUs") that were initially granted to the Reporting Person on January 25, 2023.
• F3: Includes (i) 6,250 unvested RSUs of the 50,000 RSUs granted to the Reporting Person on January 25, 2023, (ii) 21,406 unvested RSUs of the 57,085 RSUs granted to the Reporting Person on January 11, 2024, (iii) 31,787 unvested RSUs of the 50,861 RSUs granted to the Reporting Person on January 11, 2025, (iv) 18,750 unvested RSUs of the 25,000 RSUs granted to the Reporting Person on July 1, 2025, (v) 23,728 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4 and (vi) 3,964 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.